Clinical Performance and Cost Effectiveness of Biatain® Silicone Compared With Standard of Care

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-30

Study Completion Date

2023-12-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomised controlled investigation comparing the clinical performance and cost effectiveness of Biatain® Silicone with Standard of Care dressing including filler in chronic wounds (CP351 - BISIL Study)

This study (BISIL) will compare the Biatain® Silicone dressing to commonly used wound care products (AQUACEL®EXTRATM Hydrofiber® Dressing used with Mepilex® Border).

The study will recruit in total 100 adult subjects with a venous leg ulcer or a diabetic foot ulcer no deeper than 2cm. Only ulcers with a duration of at least 8 weeks but no longer than a year will be included. The study will be a randomised controlled trial where half of the participants will use Biatain® Silicone and half will use the comparator for 4 weeks. Each participant will be in the study for 4-5 weeks during which there will be a weekly visit with the study team to complete the study assessments and change the dressing. The study will run for approximately one year, starting in January 2023.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers

NCT05923749

Wound Heal

COMPLETED NA

Investigation of the Clinical Performance of Biatain Fiber Ag on Venous Leg Ulcers

NCT05873257

Venous Leg Ulcer

COMPLETED NA

Biatain Ag vs Biatain in the Treament of Leg Ulcers

NCT00807664

Leg Ulcers

COMPLETED NA

Compare Aquacel® Ag Versus Mepilex® Border Ag to Manage Bioburden in Leg Ulcers

NCT01427491

Leg Ulcers

COMPLETED PHASE3

Evaluation of Woulgan in Diabetic Foot Ulcer

NCT02631512

Diabetic Foot Ulcers

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomised controlled investigation comparing the clinical performance and cost effectiveness of Biatain® Silicone with Standard of Care dressing including filler in chronic wounds (CP351 - BISIL Study)

The properties of a wound dressing can have a significant impact on wound healing and on the risk of developing infections. The ideal wound dressing should have good contact with the wound and be effective in absorbing and holding fluids. Biatain® Silicone uses 3DFit technology, which may support better contact with the wound, help to absorb fluid more effectively and reduce the risk of leakage. These properties may support faster wound healing and reduce complications.

This study (BISIL) will compare the Biatain® Silicone dressing to commonly used wound care products (AQUACEL®EXTRATM Hydrofiber® Dressing used with Mepilex® Border). All products used in this study are CE-marked medical devices which are already available in the UK. The main objective is to compare the reduction in wound area over four weeks between the two treatment groups. The study will also look at other aspects of wound healing and compare the costs of the dressings and the participants' quality of life during the study period. In a subgroup of participants, ultrasound will be used to assess the contact between the dressings and the wound.

The study will recruit in total 100 adult subjects with a venous leg ulcer or a diabetic foot ulcer no deeper than 2cm. Only ulcers with a duration of at least 8 weeks but no longer than a year will be included. Participants will be inpatients or outpatients recruited through 12-18 Tissue Viability Units and hospitals across the UK. The study will be a randomised controlled trial where half of the participants will use Biatain® Silicone and half will use the comparator for 4 weeks. Each participant will be in the study for 4-5 weeks during which there will be a weekly visit with the study team to complete the study assessments and change the dressing. The study will run for approximately one year, starting in January 2023.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Leg Ulcer Diabetic Foot Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The clinical investigation is a two-arms, open-labelled, stratified, randomized, controlled, multicentre investigation comparing the clinical performance of Biatain® Silicone with standard of care in chronic wounds with wound depth down to 20 mm.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mepilex Border with Aquacel Extra Hydrofiber

Standard of care (filler, that functions as a primary dressing to manage exudate and the gap/space between the wound bed and the dressing, covered by a secondary dressing on top) defined in this study as Mepilex® Border with AQUACEL® Extra Hydrofiber Dressing

Group Type ACTIVE_COMPARATOR

Mepilex Border with Aquacel Extra Hydrofiber

Intervention Type DEVICE

Wound care dressing

Biatain® Silicone

The investigational test product is Biatain® Silicone. Biatain® Silicone is intended to be used for moist wound healing and exudate management and can be used without a filler.

Group Type EXPERIMENTAL

Biatain® Silicone

Intervention Type DEVICE

Wound care dressing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biatain® Silicone

Wound care dressing

Intervention Type DEVICE

Mepilex Border with Aquacel Extra Hydrofiber

Wound care dressing

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has given written consent to participate by signing the Informed Consent Signature Form
* Is at least 18 years of age and has full legal capacity
* Has a venous leg ulcer (VLU) (C6 of the CEAP classification(1)) or a non-infected diabetic foot ulcer (DFU) with a duration longer than 8 weeks but no longer than 24 months
* Has a wound with depth1 down to 20 mm
* Has a maximum wound depth1 relative to wound diameter
* Has a wound with exudate levels requiring a filler and a standard secondary dressing
* Has acceptance of compression therapy in case of a VLU or off-loading in case of a DFU, according to local standards
* For subjects with diabetes, has HbA1c ≤ 10% or ≤ 86 mmol/mol, measured within the last 3 months prior to inclusion

Exclusion Criteria

* Wound is infected. For DFUs, has infection severity mild-severe according to the IWGDF/IDSA guideline For VLUs, has 2 or more clinical signs of infection as defined in protocol, based on clinical judgement by investigator/tissue viability nurse
* Wounds is with exposed tendons, is with bones or has fistulas
* Wound is with cavity, or is undermined or tunnelling
* Subject is receiving chemotherapy
* Subject has ankle-brachial pressure index (ABPI) below 0.8 measured within one month prior to inclusion
* Wound is larger than 10 x10 cm
* Currently enrolled in another wound care de-vice investigation unless co-enrolment has been agreed with the sponsor

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No